Skip to main navigation Skip to search Skip to main content

Platelet function in rheumatoid arthritis: Arthritic and cardiovascular implications

  • Armen Yuri Gasparyan
  • , Antonios Stavropoulos-Kalinoglou
  • , Dimitri P. Mikhailidis
  • , Karen M J Douglas
  • , George D. Kitas

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Patients with rheumatoid arthritis (RA) are at high risk of cardiovascular events. Platelet biomarkers are involved in inflammation, atherosclerosis and thrombosis. Cardiovascular and RA-associated factors can alter the structure and function of platelets, starting from megakaryocytopoiesis. Reactive megakaryocytopoiesis increases circulating platelets count and triggers hyperactivity. Hyperactive platelets target synovial membranes with subsequent local rheumatoid inflammation. Hyperactive platelets interact with other cells, and target the vascular wall. Accumulating evidence suggests that disease modifying anti-rheumatic drugs (DMARD) decrease platelet activity. © Springer-Verlag 2010.
    Original languageEnglish
    Pages (from-to)153-164
    Number of pages11
    JournalRheumatology International
    Volume31
    Issue number2
    DOIs
    Publication statusPublished - Feb 2011

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Biomarkers
    • Cardiovascular risk
    • Inflammation
    • Platelet function
    • Rheumatoid arthritis

    Fingerprint

    Dive into the research topics of 'Platelet function in rheumatoid arthritis: Arthritic and cardiovascular implications'. Together they form a unique fingerprint.

    Cite this